Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry

Background The impact of statins on COVID-19 outcomes is important given the high prevalence of their use among individuals at risk for severe COVID-19. Our aim is to assess whether patients receiving chronic statin treatment who are hospitalized with COVID-19 have reduced in-hospital mortality if statin therapy is maintained during hospitalization. Methods This work is a cross-sectional, observational, retrospective multicenter study that analyzed 2921 patients who required hospital admission at 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics and COVID-19 disease outcomes between patients receiving chronic statin therapy who maintained this therapy during hospitalization versus those who did not. Propensity score matching was used to match each statin user whose therapy was maintained during hospitalization to a statin user whose therapy was withdrawn during hospitalization. Results After propensity score matching, continuation of statin therapy was associated with lower all-cause mortality (OR 0.67, 0.54–0.83, p < 0.001); lower incidence of acute kidney injury (AKI) (OR 0.76,0.6–0.97, p = 0.025), acute respiratory distress syndrome (ARDS) (OR 0.78, 0.69- 0.89, p < 0.001), and sepsis (4.82% vs 9.85%, p = 0.008); and less need for invasive mechanical ventilation (IMV) (5.35% vs 8.57, p < 0.001) compared to patients whose statin therapy was withdrawn during hospitalization. Conclusions Patients previously treated with statins who are hospitalized for COVID-19 and maintain statin therapy during hospitalization have a lower mortality rate than those in whom therapy is withdrawn. In addition, statin therapy was associated with a decreased probability that patients with COVID-19 will develop AKI, ARDS, or sepsis and decreases the need for IMV..

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:81

Enthalten in:

Drugs - 81(2021), 6 vom: 29. März, Seite 685-695

Sprache:

Englisch

Beteiligte Personen:

Torres-Peña, José David [VerfasserIn]
Pérez-Belmonte, Luis M. [VerfasserIn]
Fuentes-Jiménez, Francisco [VerfasserIn]
López Carmona, Mª Dolores [VerfasserIn]
Pérez-Martinez, Pablo [VerfasserIn]
López-Miranda, José [VerfasserIn]
Carrasco Sánchez, Francisco Javier [VerfasserIn]
Vargas Núñez, Juan Antonio [VerfasserIn]
del Corral Beamonte, Esther [VerfasserIn]
Magallanes Gamboa, Jeffrey Oskar [VerfasserIn]
González García, Andrés [VerfasserIn]
González Moraleja, Julio [VerfasserIn]
Cortés Troncoso, Andrés [VerfasserIn]
Taboada Martínez, María Luisa [VerfasserIn]
del Fidalgo Montero, María del Pilar [VerfasserIn]
Seguí Ripol, José Miguel [VerfasserIn]
Gil Sánchez, Ricardo [VerfasserIn]
Alegre González, Diana [VerfasserIn]
Boixeda, Ramon [VerfasserIn]
Cortés Rodríguez, Begoña [VerfasserIn]
Ena, Javier [VerfasserIn]
García García, Gema María [VerfasserIn]
Ventura Esteve, Ana [VerfasserIn]
Ramos Rincón, José Manuel [VerfasserIn]
Gómez-Huelgas, Ricardo [VerfasserIn]

Links:

Volltext [lizenzpflichtig]

BKL:

44.40$jPharmazie$jPharmazeutika

44.38$jPharmakologie

Anmerkungen:

© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021

doi:

10.1007/s40265-021-01498-x

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

OLC2125323923

Zugang & Verfügbarkeit




Zugehörige Publikationen/Bände

    Haven't found what you're looking for?